Received May 14, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
Several adult patients received pediatric dose of Havrix; Several adult patients received pediatric dose of Havrix; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of adult use of a child product in a adult patient who received HAV (Havrix pediatric) for prophylaxis. On an unknown date, the patients received Havrix pediatric. On an unknown date, an unknown time after receiving Havrix pediatric, the patient experienced adult use of a child product (Verbatim: Several adult patients received pediatric dose of Havrix) and underdose (Verbatim: Several adult patients received pediatric dose of Havrix). The outcome of the adult use of a child product and underdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 07-MAY-2025 The several adult patients received pediatric dose of Havrix which led to Adult use of a child product and Underdose. Seeking information on vaccination next steps.